Trial Profile
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jan 2024
Price :
$35
*
At a glance
- Drugs Ladiratuzumab-Vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE721
- Sponsors Seagen
- 12 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Planned primary completion date changed from 30 Apr 2023 to 31 Mar 2024.
- 10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium.